Financing - February 24, 2026
Oncopeptides carries out a rights issue of approx SEK 200 million
The Board of Directors has resolved to carry out a new share issue of approximately SEK 200 million with preferential rights for the company’s existing shareholders based on the authorization granted by the Annual General Meeting on 22 May 2025.
Agreement - February 23, 2026
Affibody signs Letter of Intent with SHINE Technologies
A Letter of Intent (LOI) has been signed with SHINE Technologies as an additional supplier of non-carrier-added Lutetium-177 (n.c.a. Lu-177).
Legal Advice article - February 10, 2026
Novo Nordisk sues Hims & Hers over alleged unsafe Wegovy and Ozempic knock‑offs
On 9 February 2026, Novo Nordisk announced it has filed a lawsuit against U.S. telehealth company Hims & Hers, alleging that the firm is offering compounded, non‑FDA‑approved versions of Wegovy and Ozempic that could put patients at risk.
Biotech Business - February 4, 2026
Cereno Scientific broadens development focus for CS014
Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Agreement - January 30, 2026
Bavarian Nordic signs distribution agreement with Eurofarma
Bavarian Nordic has announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil.
Global report - January 30, 2026
AstraZeneca enhances its weight management portfolio
AstraZeneca has entered a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.
